In vitro and in vivo activities of posaconazole against Coccidioides immitis

Gloria M. González, Rolando Tijerina, Laura K. Najvar, Rosie Bocanegra, Michael Rinaldi, David Loebenberg, John R. Graybill

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Abstract

Posaconazole (SCH 56592) was tested against 25 strains of Coccidioides immitis to determine their in vitro susceptibilities. The geometric mean 48-h MIC of posaconazole (POSA) was 0.5 μg/ml, the MIC range was 0.25 to 1 μg/ml, and the MIC at which 50% of the isolates tested are inhibited (MIC50) and the MIC90 were 0.5 and 1 μg/ml, respectively. The geometric mean 48-h MIC of itraconazole (ITRA) was 0.23 μg/ml, the MIC range was 0.125 to 0.5 μg/ml, and the MIC50 and MIC90 were both 0.25 μg/ml. Two strains of C. immitis were selected for in vivo studies on the basis of the POSA 48-h MICs for the isolates. POSA orally administered at 0.01, 0.1, 0.5, 1, 5, and 10 mg/kg of body weight/day was compared with ITRA administered at 10 and 30 mg/kg three times a day. The spleens and livers of mice that died or survived to day 50 were removed to measure the fungal burdens. Mice had ≥90% survival when they were treated with ≥0.5 mg of POSA per kg or 30 mg of ITRA per kg. Cultures of whole spleens and livers from mice treated with 10 mg of POSA per kg showed ≥70% sterilization. No sterilization of whole spleens and livers from mice treated with ITRA was seen. POSA displayed potent in vivo activity against the two strains of C. immitis tested.

Original languageEnglish (US)
Pages (from-to)1352-1356
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume46
Issue number5
DOIs
StatePublished - 2002
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'In vitro and in vivo activities of posaconazole against Coccidioides immitis'. Together they form a unique fingerprint.

Cite this